The Spanish Drug Market In First-Quarter 1996

28 July 1996

Consumption in Spain of prescription and over-the-counter pharmceutical products amounted to 164.4 billion pesetas ($1.3 billion) in the first quarter of 1996, an increase of 8.4%, according to the Spanish Office of Health Economics' Bulletin for July.

The Spanish prescription drug market is becoming more and more affected by public consumption (reimbursement through social security), which in three years has expanded its participation from 73.4% to 79.6%. This increase is also present in terms of the numbers of units sold, said the Spanish OHE. In terms of units sold, the rise was from 62.2% in the first three months of 1993 to 66.5% in the first three months of 1996.

Consumption of OTC products in the first quarter represented 5.55% of the total market in 1993, and 6.45% in the 1996 first quarter. In terms of units sold, the market share for OTC products grew from 4% in 1993 to 16.3% of the total market in the 1996 first quarter.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight